Crystal structure of rhodopsin: a G protein-coupled receptor. Palczewski K,*(1) kumasaka T, hori T, behnke CA, motoshima H, fox BA, trong IL, teller DC, okada T, stenkamp RE, yamamoto M, miyano M. Science 2000;289:739-745

Autor: Craig Behnke

Publikováno v: American journal of ophthalmology. 130(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739ee28fbdf98405e3c7c5ebc109a3b1
https://pubmed.ncbi.nlm.nih.gov/11124332

Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.

Autor: Tokuhara H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan., Imaeda Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Fukase Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Iwanaga K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Taya N; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan., Watanabe K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kanagawa R; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; PRA Health Sciences KK, 3-8, Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan., Matsuda K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; SCOHIA PHARMA Inc., 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kajimoto Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; SPERA PHARMA,1nc., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-0024, Japan., Kusumoto K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kondo M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan; Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan., Snell G; Takeda California, Inc, 10410 Science Center Drive, San Diego, CA 92121, United States., Behnke CA; Takeda California, Inc, 10410 Science Center Drive, San Diego, CA 92121, United States; 10996 Torreyana Rd. Suite 280, San Diego, CA 92121, United States., Kuroita T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: takanobu.kuroita@takeda.com.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2018 Jul 23; Vol. 26 (12), pp. 3261-3286. Date of Electronic Publication: 2018 Apr 27.

Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.

Autor: Imaeda Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: yasuhiro.imaeda@takeda.com., Tawada M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Suzuki S; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Tomimoto M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Kondo M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Tarui N; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Sanada T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Kanagawa R; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Snell G; Takeda California, Inc., 10410, Science Center Drive, San Diego, CA 92121, United States., Behnke CA; Takeda California, Inc., 10410, Science Center Drive, San Diego, CA 92121, United States., Kubo K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan., Kuroita T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2016 Nov 15; Vol. 24 (22), pp. 5771-5780. Date of Electronic Publication: 2016 Sep 13.

Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.

Autor: Imaeda Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Tokuhara H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Fukase Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kanagawa R; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kajimoto Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kusumoto K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kondo M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Snell G; Takeda California, Inc. , 10410 Science Center Drive, San Diego, California 92121, United States., Behnke CA; Takeda California, Inc. , 10410 Science Center Drive, San Diego, California 92121, United States., Kuroita T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2016 Sep 12; Vol. 7 (10), pp. 933-938. Date of Electronic Publication: 2016 Sep 12 (Print Publication: 2016).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.